Mesothelioma & Asbestos

The number of people diagnosed with asbestos caused diseases in the U.S. continues to increase. Experts believe 60,000 mesothelioma deaths will occur between 2010 and 2030.

Industrial Accidents

Work related injuries harm up to 14 million people annually, with harms including traumatic brain injuries, spinal injuries, amputations, burns, and electrocutions. Around 20,000 to 60,000 workers die each year from accidents, toxins, and violence at their jobs.

Product Defects

Millions of consumers and workers are injured each year because of defective products. Defects can occur when a product is designed poorly, when a product is manufactured in a manner that differs from the intended design, or when the product does not contain proper warnings or instructions. Defects can occur in automobiles, pharmaceuticals, medical devices, construction equipment, toys, and other goods.

Nursing Home Abuse

Between 1.5 and 2 million elderly reside in nursing home facilities, with studies revealing that 44% have suffered some form of abuse. Many believe the actual number of residents suffering abuse is much higher. Neglect and abuse may result in serious emotional, physical, and financial harm

Our Experience

Paul & Hanley’s legal team has produced some of the most notable verdicts and highest settlements in the United States. Over 500 of our clients have each obtained in excess of 1 million dollars. Over 250 have recovered multi-million dollar recoveries.

< Back Pause Next >

Home ›

AZD 2171 Clinical Trial

Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery
 
Alternate Title:  AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
 
Objectives:
 
Primary
  1. Determine the objective response rate in patients with malignant pleural, peritoneal, or tunica vaginalis mesothelioma that is not amenable to curative surgery who are treated with AZD2171.
 Secondary
  1. Determine the progression-free survival of patients treated with AZD2171.
  2. Determine the toxicity experienced by patients treated with AZD2171.
  3. Determine median and overall survival of patients treated with AZD2171.
Tertiary
  1. Generate preliminary data regarding potential utility of pharmacogenomic and plasma/serum biomarkers of angiogenesis as predictive or prognostic markers for future investigations of this drug in malignant mesothelioma.
Outline: 
 
This is a multicenter study. Patients receive oral ADZ2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients undergo blood collection periodically during study for biomarker and optional pharmacogenomic correlative studies. After completion of study treatment, patients are followed for up to 8 weeks.
 
Trial Sites:  California, Illinois, Indiana, Michigan, Pennsylvania, Wisconsin, Ontario 
 
 

Free Case Evaluation Form (800) 281-9804

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Free Case Evaluation Form (800) 281-9804